Last reviewed · How we verify
PRAZOSIN HYDROCHLORIDE
Prazosin Hydrochloride is a marketed drug primarily indicated for hypertension, with a key composition patent expiring in 2028. Its long-standing market presence and established mechanism of action provide a strong foundation in the hypertension treatment landscape. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | PRAZOSIN HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1976 |
Approved indications
- Hypertension
Common side effects
- dizziness
- headache
- drowsiness
- lack of energy
- weakness
- palpitations
- nausea
Key clinical trials
- Alpha-1 Blockade for Alcohol Use Disorder (AUD) (PHASE2)
- A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults (PHASE1)
- Brain Blood Vessel Responses to Changes in Blood Flow (PHASE2)
- Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests (PHASE3)
- Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort (PHASE2)
- Prazosin for Alcohol Use Disorder With Withdrawal Symptoms (PHASE2)
- Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder (PHASE2)
- Doxazosin an a1 Antagonist for Alcohol Dependence (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRAZOSIN HYDROCHLORIDE CI brief — competitive landscape report
- PRAZOSIN HYDROCHLORIDE updates RSS · CI watch RSS